Circulating Tumor DNA as a Prognostic Biomarker for Selecting Participants to Early Phase Clinical Trials.
Saved in:
| Title: | Circulating Tumor DNA as a Prognostic Biomarker for Selecting Participants to Early Phase Clinical Trials. |
|---|---|
| Authors: | Shaya S; The Christie NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, United Kingdom., Uche-Ikonne O; The Christie NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, United Kingdom., Kilerci B; Cancer Research UK Manchester Institute, Manchester, United Kingdom., Stevenson J; Digital Experimental Cancer Medicine Team, Cancer Research UK Manchester Institute, Manchester, United Kingdom., Greystoke A; Sir Bobby Robson Cancer Trials Research Centre, Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, United Kingdom.; Newcastle University, Newcastle upon Tyne, United Kingdom., Cook N; The Christie NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, United Kingdom.; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, United Kingdom., Thistlethwaite FC; The Christie NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, United Kingdom.; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, United Kingdom., Carter L; The Christie NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, United Kingdom.; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, United Kingdom., Graham DM; The Christie NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, United Kingdom.; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, United Kingdom., Krebs MG; The Christie NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, United Kingdom.; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, United Kingdom. |
| Source: | Journal of immunotherapy and precision oncology [J Immunother Precis Oncol] 2025 Aug 25; Vol. 8 (3), pp. 222-232. Date of Electronic Publication: 2025 Aug 25 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Innovative Healthcare Institute Country of Publication: United States NLM ID: 101768397 Publication Model: eCollection Cited Medium: Internet ISSN: 2590-017X (Electronic) Linking ISSN: 2590017X NLM ISO Abbreviation: J Immunother Precis Oncol Subsets: In Process |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
